Autres langues Apollomics, Inc.

Actions

APLM

KYG0411D1236

Sociétés holdings

Marché Fermé - Nasdaq 22:30:00 01/10/2026			Varia. 5j.	Varia. 1 janv.
23,27 ^USD	-6,75%		+4,10%	+24,45%

18/08	Un dirigeant d'Apollomics achète des actions pour une valeur de 7 550 004 $, selon une récente déclaration à la SEC	MT
21/07	Apollomics Inc. annonce des changements au sein de son conseil d'administration et de ses comités, effectifs au 20 juillet 2026	CI

Autres langues

19/08	Apollomics, Inc. announced that it has received $8.00001 million in funding from Maxpro Investment Co., Ltd. and other investors.
19/08	Apollomics, Inc. announced that it has received $8.00001 million in funding from Maxpro Investment Co., Ltd. and other investors.
18/08	Apollomics Insider Bought Shares Worth $7,550,004, According to a Recent SEC Filing
11/08	Apollomics Announces $10 Million Private Placement Transaction
21/07	Apollomics Inc. Announces Board and Committee Changes, Effective July 20, 2026
13/07	Apollomics Regains Full Compliance with Nasdaq Listing Requirements
24/06	Apollomics Receives Nasdaq Deficiency Notice Over Market Value Requirement
24/06	Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
27/04	Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
24/04	Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
24/04	Apollomics, Inc. Auditor Raises 'Going Concern' Doubt
01/04	Apollomics Inc. Announces $2.0 Million Bridge Financing
30/03	Apollomics, Inc. announced that it expects to receive $2 million in funding
22/12	Apollomics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025
22/12	Apollomics Reports First Half 2025 Financial Results
19/11	Apollomics Announces Settlement of Cayman Litigation
19/11	Apollomics entered settlement agreement related to legal proceedings by two minority investors of co
18/11	Apollomics Announces Changes to its Board of Directors and Composition of Committees
18/11	Apollomics Announces Changes in Board and Committees, Effective from November 16, 2025
21/10/25	Apollomics received a payment of US$3.9 million from Launxp
16/10/25	Top Midday Gainers
15/10/25	Apollomics Receives Compliance Notification From Nasdaq
15/10/25	Apollomics announces continued listing on Nasdaq following hearing cancellation
15/10/25	Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
14/10/25	Nasdaq Resumes Trading in Apollomics Inc.